38647-79-9 Usage
General Description
Urefibrate is a chemical compound that belongs to the class of fibrates, which are used in the treatment of high cholesterol and triglyceride levels. It works by reducing the production of cholesterol and increasing the breakdown of triglycerides in the body. Urefibrate also has anti-inflammatory properties and can help improve insulin sensitivity. It is commonly used as a medication to lower the risk of cardiovascular diseases and can be prescribed in combination with a healthy diet and exercise regimen. Some common side effects of urefibrate include stomach upset, muscle pain, and an increased risk of developing gallstones. It is important to consult with a healthcare professional before using urefibrate to ensure it is the right treatment option for individual needs.
Check Digit Verification of cas no
The CAS Registry Mumber 38647-79-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,6,4 and 7 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 38647-79:
(7*3)+(6*8)+(5*6)+(4*4)+(3*7)+(2*7)+(1*9)=159
159 % 10 = 9
So 38647-79-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H12Cl2N2O4/c16-9-1-5-11(6-2-9)22-14(13(20)19-15(18)21)23-12-7-3-10(17)4-8-12/h1-8,14H,(H3,18,19,20,21)
38647-79-9Relevant articles and documents
Synthesis and pharmacological evaluation of N'-morpholinomethylurea derivatives with platelet antiaggregant activity
Ribalta,Artus,Salvador,Roma,Vilageliu,Freixes,Bruseghini
, p. 1782 - 1786 (2007/10/02)
In the attempt to prolong and stabilize the known antiaggregant activity of morpholinomethylurea (MMU) derivatives were prepared with carboxylic acids possessing antiaggregant, antiinflammatory or hypolipemic activity. The results of the experiments showed the important anti-aggregant and hypolipemic activity of N-2(p-chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, ITA 104). The results obtained seem to indicate that the activity of these new N-acyl-N'-MMU is due initially to the molecule per se although it cannot be totally ruled out that part of the pharmacodynamic effect of the MMU may depend on a prodrug-like behaviour.
